Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment
出版年份 2021 全文链接
标题
Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment
作者
关键词
-
出版物
Cancers
Volume 13, Issue 24, Pages 6231
出版商
MDPI AG
发表日期
2021-12-13
DOI
10.3390/cancers13246231
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes
- (2021) Diego Salas-Benito et al. BRITISH JOURNAL OF CANCER
- The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer
- (2021) Arafath K. Najumudeen et al. NATURE GENETICS
- Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer
- (2021) Rodney P. Rocconi et al. GYNECOLOGIC ONCOLOGY
- Lymphopenia-induced lymphoproliferation drives activation of naive T cells and expansion of regulatory populations
- (2021) Eldershaw S et al. iScience
- Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer
- (2021) Yu Rebecca Miao et al. CLINICAL CANCER RESEARCH
- Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer
- (2021) Chi Yan et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
- (2021) Andrés Poveda et al. LANCET ONCOLOGY
- The regulation of immune checkpoints by the hypoxic tumor microenvironment
- (2021) Min Hu et al. PeerJ
- CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
- (2021) Navid Sobhani et al. Cancers
- Comparing the frequency of CD33 + pSTAT3 + myeloid‐derived suppressor cells and IL‐17 + lymphocytes in patients with prostate cancer and benign prostatic hyperplasia
- (2021) Mohammad‐Javad Sanaei et al. CELL BIOLOGY INTERNATIONAL
- Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer
- (2021) Carolyn N. Krasner et al. GYNECOLOGIC ONCOLOGY
- Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial
- (2021) David Cibula et al. GYNECOLOGIC ONCOLOGY
- Oophorectomy significantly impacts response to immune therapy regimens in preclinical models of ovarian cancer
- (2021) Marina Miller et al. GYNECOLOGIC ONCOLOGY
- Lactic acid in macrophage polarization: The significant role in inflammation and cancer
- (2021) Hai-cun Zhou et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
- (2021) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
- (2021) Bradley J Monk et al. LANCET ONCOLOGY
- Ovarian Cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells
- (2021) Cláudia Rodrigues Tonetti et al. Cells
- Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer
- (2020) Bihui Cao et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
- (2020) Shin Nishio et al. CANCER SCIENCE
- Assessment of acyl-CoA cholesterol acyltransferase (ACAT-1) role in ovarian cancer progression—An in vitro study
- (2020) Vijayalakshmi N. Ayyagari et al. PLoS One
- CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer
- (2020) Christina Friese et al. Scientific Reports
- Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
- (2020) David S. Hong et al. BRITISH JOURNAL OF CANCER
- Arginine depletion therapy with ADI-PEG20 limits tumor growth in argininosuccinate synthase deficient ovarian cancer, including small cell carcinoma of the ovary, hypercalcemic type
- (2020) Jennifer X Ji et al. CLINICAL CANCER RESEARCH
- The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors
- (2020) Denisa Baci et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
- (2020) K. Esther Broekman et al. INVESTIGATIONAL NEW DRUGS
- Pembrolizumab plus allogeneic NK cells in advanced non–small cell lung cancer patients
- (2020) Mao Lin et al. JOURNAL OF CLINICAL INVESTIGATION
- APOLLO: A phase I study of adaptive memory natural killer (NK) cells in recurrent ovarian cancer.
- (2020) Melissa Ann Geller et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I combination study of vigil and atezolizumab in recurrent/refractory advanced-stage ovarian cancer: Efficacy assessment in BRCA1/2-wt patients.
- (2020) Rodney Paul Rocconi et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study
- (2020) Dmitriy Zamarin et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-VEGF Treatment Enhances CD8+ T-cell Antitumor Activity by Amplifying Hypoxia
- (2020) Patricia E. de Almeida et al. Cancer Immunology Research
- Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)
- (2020) Philipp Harter et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells
- (2020) Min-Hee Oh et al. JOURNAL OF CLINICAL INVESTIGATION
- Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
- (2020) Lorenzo Galluzzi et al. Nature Reviews Clinical Oncology
- Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
- (2020) Luis Felipe Campesato et al. Nature Communications
- Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer
- (2020) Anders Handrup Kverneland et al. Oncotarget
- Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer
- (2020) Jason R Brown et al. JCI Insight
- Bufalin inhibits ovarian carcinoma via targeting mTOR/HIF‐α pathway
- (2020) Shan Su et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression
- (2020) Ahmed Sadik et al. CELL
- Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients
- (2020) Matthew S. Block et al. Nature Communications
- PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response
- (2020) Chiho Kim et al. eLife
- Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer
- (2020) Ana Oaknin et al. JAMA Oncology
- Transforming growth factor beta type 1 (TGF-β) and hypoxia-inducible factor 1 (HIF-1) transcription complex as master regulators of the immunosuppressive protein galectin-9 expression in human cancer and embryonic cells
- (2020) Anette Teo Hansen Selnø et al. Aging-US
- Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
- (2020) Rodney P Rocconi et al. LANCET ONCOLOGY
- Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer
- (2020) Emese Zsiros et al. JAMA Oncology
- Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
- (2019) Xianjie Jiang et al. Molecular Cancer
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
- (2019) Mary L. Disis et al. JAMA Oncology
- Navigating metabolic pathways to enhance antitumour immunity and immunotherapy
- (2019) Xiaoyun Li et al. Nature Reviews Clinical Oncology
- Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study)
- (2019) Janneke Hoogstad-van Evert et al. MEDICINE
- Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
- (2019) Parisa Malekzadeh et al. JOURNAL OF CLINICAL INVESTIGATION
- Cytotoxicity of [HuArgI (co)-PEG5000]-induced arginine deprivation to ovarian Cancer cells is autophagy dependent
- (2019) Ghenwa Nasreddine et al. INVESTIGATIONAL NEW DRUGS
- Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer
- (2019) Rüdiger Klapdor et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- In Vivo Persistence and Function of Adaptive NK Cell Infusions (FATE-NK100) from CMV Seropositive Haploidentical Related Donors
- (2019) Sarah Cooley et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- (2019) O Hamid et al. ANNALS OF ONCOLOGY
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study
- (2019) U A Matulonis et al. ANNALS OF ONCOLOGY
- Transforming Growth Factor-β Signaling in Immunity and Cancer
- (2019) Eduard Batlle et al. IMMUNITY
- Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
- (2019) Takahiro Kamiya et al. JOURNAL OF CLINICAL INVESTIGATION
- DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.
- (2019) Philipp Harter et al. JOURNAL OF CLINICAL ONCOLOGY
- Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39
- (2019) Maisa C. Takenaka et al. NATURE NEUROSCIENCE
- Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance
- (2019) Meran Keshawa Ediriweera et al. SEMINARS IN CANCER BIOLOGY
- Role of Mitochondria in the Mechanism(s) of Action of Metformin
- (2019) Guillaume Vial et al. Frontiers in Endocrinology
- Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer
- (2019) Minna Sopo et al. BMC CANCER
- Dose-ranging and cohort-expansion study of monalizumab(IPH2201) in advanced gynecologic malignancies:A trial of the Canadian Cancer Trials Group (CCTG):IND221
- (2019) Anna V Tinker et al. CLINICAL CANCER RESEARCH
- Correlation of the Aryl Hydrocarbon Receptor with FSHR in Ovarian Cancer Patients
- (2019) Eileen Deuster et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
- (2019) Edward B. Garon et al. JOURNAL OF CLINICAL ONCOLOGY
- CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
- (2019) Amira A. Barkal et al. NATURE
- Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients
- (2019) Tommy A. Brown et al. Cancer Medicine
- Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer
- (2019) Thaïs Baert et al. Frontiers in Immunology
- Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers
- (2019) Joyce F. Liu et al. GYNECOLOGIC ONCOLOGY
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- PGC-1α activator–induced fatty acid oxidation in tumor-infiltrating CTLs enhances effects of PD-1 blockade therapy in lung cancer
- (2019) Huan Wan et al. TUMORI
- Hypoxia-Inducible Factor-1α (HIF-1α) Promotes Hypoxia-Induced Invasion and Metastasis in Ovarian Cancer by Targeting Matrix Metallopeptidase 13 (MMP13)
- (2019) Hui Zhang et al. MEDICAL SCIENCE MONITOR
- Therapeutic strategies for the costimulatory molecule OX40 in T-cell mediated immunity
- (2019) Yu Fu et al. Acta Pharmaceutica Sinica B
- 440OPhase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours
- (2019) A Naing et al. ANNALS OF ONCOLOGY
- 1190PDPhase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)
- (2019) Y Drew et al. ANNALS OF ONCOLOGY
- Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors
- (2019) An Coosemans et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
- (2019) Franck Morschhauser et al. MOLECULAR CANCER THERAPEUTICS
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
- (2019) Robert D. Leone et al. SCIENCE
- The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
- (2019) Weiting Qin et al. Frontiers in Immunology
- Reprogramming of fatty acid metabolism in cancer
- (2019) Nikos Koundouros et al. BRITISH JOURNAL OF CANCER
- CXCR1 Expression to Improve Anti-Cancer Efficacy of Intravenously Injected CAR-NK Cells in Mice with Peritoneal Xenografts
- (2019) Yu Yang Ng et al. Molecular Therapy-Oncolytics
- Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells
- (2018) Ailin Li et al. CANCER LETTERS
- Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer
- (2018) Lifeng Li et al. CANCER RESEARCH
- LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer
- (2018) Masoud F. Tavazoie et al. CELL
- Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy
- (2018) Tina Cascone et al. Cell Metabolism
- Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
- (2018) Ye Li et al. Cell Stem Cell
- p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy
- (2018) Nicola R. Hardwick et al. CLINICAL CANCER RESEARCH
- Involvement of CD24 in Multiple Cancer Related Pathways Makes It an Interesting New Target for Cancer Therapy
- (2018) Shirin Eyvazi et al. CURRENT CANCER DRUG TARGETS
- IL-2 and Beyond in Cancer Immunotherapy
- (2018) John M. Wrangle et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
- (2018) Petar Jelinic et al. JNCI-Journal of the National Cancer Institute
- Fatty acid oxidation contributes to IL-1β secretion in M2 macrophages and promotes macrophage-mediated tumor cell migration
- (2018) Qi Zhang et al. MOLECULAR IMMUNOLOGY
- Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme
- (2018) Todd A Triplett et al. NATURE BIOTECHNOLOGY
- A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
- (2018) Daniela S. Thommen et al. NATURE MEDICINE
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation
- (2018) Angela Russo et al. ONCOGENE
- The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies
- (2018) Hui Luo et al. PLoS One
- Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth
- (2018) Ilenia Pacella et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
- (2018) Janos L. Tanyi et al. Science Translational Medicine
- The role of hypoxia in shaping the recruitment of proangiogenic and immunosuppressive cells in the tumor microenvironment
- (2018) Salem Chouaib et al. Wspolczesna Onkologia-Contemporary Oncology
- Metformin inhibits proliferation and cytotoxicity and induces apoptosis via AMPK pathway in CD19-chimeric antigen receptor-modified T cells
- (2018) Qian Mu et al. OncoTargets and Therapy
- Natural killer cells inhibit metastasis of ovarian carcinoma cells and show therapeutic effects in a murine model of ovarian cancer
- (2018) Yanming Sun et al. Experimental and Therapeutic Medicine
- Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
- (2018) Petar Jelinic et al. JNCI-Journal of the National Cancer Institute
- Targeting VEGF/VEGFR to Modulate Antitumor Immunity
- (2018) Ju Yang et al. Frontiers in Immunology
- Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
- (2018) Muhammad Zubair Afzal et al. Journal for ImmunoTherapy of Cancer
- Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
- (2018) Michael M. Boyiadzis et al. Journal for ImmunoTherapy of Cancer
- Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation
- (2018) Valesca P. Retèl et al. BMC CANCER
- Transcription factors WT1 and p53 combined: a prognostic biomarker in ovarian cancer
- (2018) Julia H. Carter et al. BRITISH JOURNAL OF CANCER
- Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma
- (2018) Samuel K. McBrayer et al. CELL
- Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers
- (2018) V. Chung et al. Clinical & Translational Oncology
- Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
- (2018) Tara C. Mitchell et al. JOURNAL OF CLINICAL ONCOLOGY
- TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.
- (2018) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
- (2018) Jong-Ho Cha et al. MOLECULAR CELL
- Lactate dehydrogenase is correlated with clinical stage and grade and is downregulated by si‑STAB1 in ovarian cancer
- (2018) Jiangdong Xiang et al. ONCOLOGY REPORTS
- Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study
- (2018) Magnus Pedersen et al. OncoImmunology
- The clinical role of the TME in solid cancer
- (2018) Nicolas A. Giraldo et al. BRITISH JOURNAL OF CANCER
- PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
- (2018) Jianfeng Shen et al. CANCER RESEARCH
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
- (2018) Pascale André et al. CELL
- Phase IB Dose-Escalation and Expansion Study of AKT kinase inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer
- (2018) Sarah P Blagden et al. CLINICAL CANCER RESEARCH
- Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028
- (2018) Andrea Varga et al. GYNECOLOGIC ONCOLOGY
- Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells
- (2018) Nuzhat Ahmed et al. SEMINARS IN CANCER BIOLOGY
- PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
- (2018) Liya Ding et al. Cell Reports
- Ovarian Cancer-Intrinsic Fatty Acid Synthase Prevents Anti-tumor Immunity by Disrupting Tumor-Infiltrating Dendritic Cells
- (2018) Li Jiang et al. Frontiers in Immunology
- Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
- (2018) Takefumi Komiya et al. Frontiers in Oncology
- IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer
- (2017) M. Felices et al. GYNECOLOGIC ONCOLOGY
- Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
- (2017) Matthew A. Coelho et al. IMMUNITY
- CD56bright NK cells exhibit potent antitumor responses following IL-15 priming
- (2017) Julia A. Wagner, Maximillian Rosario, Rizwan Romee, Melissa M. Berrien-Elliott, Stephanie E. Schneider, Jeffrey W. Leong, Ryan P. Sullivan, Brea A. Jewell, Michelle Becker-Hapak, Timothy Schappe, Sara Abdel-Latif, Aaron R. Ireland, Devika Jaishankar, Justin A. King, Ravi Vij, Dennis Clement, Jodie Goodridge, Karl-Johan Malmberg, Hing C. Wong, Todd A. Fehniger JOURNAL OF CLINICAL INVESTIGATION
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Continuous use of metformin can improve survival in type 2 diabetic patients with ovarian cancer
- (2017) Shan-Bing Wang et al. MEDICINE
- PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation
- (2017) Amit Gupta et al. MOLECULAR CELL
- Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors
- (2017) Jennifer Wheler et al. ONCOLOGIST
- Correction: PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
- (2017) Zhiqiang Guo et al. PLoS One
- Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
- (2017) Kenji Chamoto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Common Cytokine Receptor γ Chain Family of Cytokines
- (2017) Jian-Xin Lin et al. Cold Spring Harbor Perspectives in Biology
- IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours
- (2017) Hyungseok Seo et al. Nature Communications
- Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression
- (2017) Juan Liu et al. Nature Communications
- High grade serous ovarian carcinomas originate in the fallopian tube
- (2017) S. Intidhar Labidi-Galy et al. Nature Communications
- Microsatellite Instability
- (2017) Liisa Chang et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Reconstitution of T Cell Proliferation under Arginine Limitation: Activated Human T Cells Take Up Citrulline via L-Type Amino Acid Transporter 1 and Use It to Regenerate Arginine after Induction of Argininosuccinate Synthase Expression
- (2017) Anke Werner et al. Frontiers in Immunology
- Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
- (2017) et al. JAMA Oncology
- Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism
- (2016) Zhihong Ai et al. CANCER LETTERS
- IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer
- (2016) M. S. Caetano et al. CANCER RESEARCH
- IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis
- (2016) G. D. Brooks et al. CANCER RESEARCH
- Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity
- (2016) Laurent Beziaud et al. CANCER RESEARCH
- CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma
- (2016) J. Walton et al. CANCER RESEARCH
- L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity
- (2016) Roger Geiger et al. CELL
- Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth
- (2016) Lifeng Yang et al. Cell Metabolism
- 4-1BB signaling activates glucose and fatty acid metabolism to enhance CD8+ T cell proliferation
- (2016) Beom K Choi et al. Cellular & Molecular Immunology
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells
- (2016) Ben Davidson HUMAN PATHOLOGY
- The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction
- (2016) Nicole E. Scharping et al. IMMUNITY
- Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8 + T Cell Exhaustion
- (2016) Bertram Bengsch et al. IMMUNITY
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti–PD-1 and Anti-CD137 Monoclonal Antibodies
- (2016) Arantza Azpilikueta et al. Journal of Thoracic Oncology
- Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer
- (2016) Emma Eriksson et al. Journal of Translational Medicine
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism
- (2016) Wei Yang et al. NATURE
- Normalizing the environment recapitulates adult human immune traits in laboratory mice
- (2016) Lalit K. Beura et al. NATURE
- Emerging concepts of T cell metabolism as a target of immunotherapy
- (2016) Chih-Hao Chang et al. NATURE IMMUNOLOGY
- Durable antitumor responses to CD47 blockade require adaptive immune stimulation
- (2016) Jonathan T. Sockolosky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer
- (2016) J. Antony et al. Science Signaling
- Fatty acid metabolic reprogramming via mTOR-mediated inductions of PPARγ directs early activation of T cells
- (2016) Mulki Angela et al. Nature Communications
- Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes
- (2016) Polina Matre et al. Oncotarget
- Altered glutamine metabolism in platinum resistant ovarian cancer
- (2016) Chantelle D. Hudson et al. Oncotarget
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
- (2016) Kyle C. Strickland et al. Oncotarget
- The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer
- (2016) J. Antony et al. Science Signaling
- Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
- (2016) Nicole E. Scharping et al. Cancer Immunology Research
- Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers
- (2016) E. C. Moore et al. Cancer Immunology Research
- Recognition and Regulation of T Cells by NK Cells
- (2016) Katharina Pallmer et al. Frontiers in Immunology
- The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy
- (2016) Magdalena Paolino et al. Cancers
- Up-regulation of fatty acid synthase induced by EGFR/ERK activation promotes tumor growth in pancreatic cancer
- (2015) Yong Bian et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Mutant p53 Promotes Tumor Cell Malignancy by Both Positive and Negative Regulation of the Transforming Growth Factor β (TGF-β) Pathway
- (2015) Lei Ji et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Friends Not Foes: CTLA-4 Blockade and mTOR Inhibition Cooperate during CD8+T Cell Priming To Promote Memory Formation and Metabolic Readiness
- (2015) Virginia A. Pedicord et al. JOURNAL OF IMMUNOLOGY
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer
- (2015) Dirk O Bauerschlag et al. Journal of Translational Medicine
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K
- (2015) Rupert Courtnay et al. MOLECULAR BIOLOGY REPORTS
- Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
- (2015) Emanuela Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Fatty acid metabolism in the regulation of T cell function
- (2015) Matthias Lochner et al. TRENDS IN IMMUNOLOGY
- PTEN mediates Notch-dependent stalk cell arrest in angiogenesis
- (2015) Helena Serra et al. Nature Communications
- LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
- (2015) Ruea-Yea Huang et al. Oncotarget
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
- (2015) T. Higuchi et al. Cancer Immunology Research
- B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape
- (2015) Silvia Pesce et al. OncoImmunology
- HIF-1α pathway: role, regulation and intervention for cancer therapy
- (2015) Georgina N. Masoud et al. Acta Pharmaceutica Sinica B
- Effect of NKG2D ligand expression on host immune responses
- (2015) Marine Champsaur et al. IMMUNOLOGICAL REVIEWS
- IL4I1 Is a Novel Regulator of M2 Macrophage Polarization That Can Inhibit T Cell Activation via L-Tryptophan and Arginine Depletion and IL-10 Production
- (2015) Yinpu Yue et al. PLoS One
- Metformin Suppresses Ovarian Cancer Growth and Metastasis with Enhancement of Cisplatin Cytotoxicity In Vivo
- (2015) Ramandeep Rattan et al. NEOPLASIA
- Nanoparticle-Delivered Transforming Growth Factor-β siRNA Enhances Vaccination against Advanced Melanoma by Modifying Tumor Microenvironment
- (2014) Zhenghong Xu et al. ACS Nano
- Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria
- (2014) Hannah R. Bridges et al. BIOCHEMICAL JOURNAL
- CD47 in the Tumor Microenvironment Limits Cooperation between Antitumor T-cell Immunity and Radiotherapy
- (2014) D. R. Soto-Pantoja et al. CANCER RESEARCH
- Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment
- (2014) Yuko Tanizaki et al. CANCER SCIENCE
- p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses
- (2014) N. R. Hardwick et al. CLINICAL CANCER RESEARCH
- Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment
- (2014) Vinit Kumar et al. IMMUNOLOGY
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Macrophage Migration Inhibitory Factor Contributes to the Immune Escape of Ovarian Cancer by Down-Regulating NKG2D
- (2014) M. Krockenberger et al. JOURNAL OF IMMUNOLOGY
- Analysis of FoxP3+ T-Regulatory Cells and CD8+T-Cells in Ovarian Carcinoma: Location and Tumor Infiltration Patterns Are Key Prognostic Markers
- (2014) Cecilia Hermans et al. PLoS One
- A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients
- (2014) Meiying Zhang et al. Journal of Ovarian Research
- Targeting PI3K/Akt/mTOR Signaling in Cancer
- (2014) Camillo Porta et al. Frontiers in Oncology
- Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis
- (2013) Chih-Hao Chang et al. CELL
- Inactivation of tumor-specific CD8+ CTLs by tumor-infiltrating tolerogenic dendritic cells
- (2013) Hirotomo Harimoto et al. IMMUNOLOGY AND CELL BIOLOGY
- Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: Profile comparison
- (2013) Davide Brusa et al. INTERNATIONAL JOURNAL OF UROLOGY
- Macrophage Scavenger Receptor A Promotes Tumor Progression in Murine Models of Ovarian and Pancreatic Cancer
- (2013) C. Neyen et al. JOURNAL OF IMMUNOLOGY
- Dendritic Cell Reprogramming by Endogenously Produced Lactic Acid
- (2013) A. Nasi et al. JOURNAL OF IMMUNOLOGY
- Tumor-Derived Lactate Modifies Antitumor Immune Response: Effect on Myeloid-Derived Suppressor Cells and NK Cells
- (2013) Z. Husain et al. JOURNAL OF IMMUNOLOGY
- Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
- (2013) Jaekyoung Son et al. NATURE
- Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cells
- (2013) Sarah-Maria Fendt et al. Nature Communications
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- Plasmacytoid Dendritic Cells Promote Immunosuppression in Ovarian Cancer via ICOS Costimulation of Foxp3+ T-Regulatory Cells
- (2012) C. Conrad et al. CANCER RESEARCH
- VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
- (2012) M. Terme et al. CANCER RESEARCH
- Convergent Multi-miRNA Targeting of ApoE Drives LRP1/LRP8-Dependent Melanoma Metastasis and Angiogenesis
- (2012) Nora Pencheva et al. CELL
- AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo
- (2012) Brandon Faubert et al. Cell Metabolism
- Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence
- (2012) M. T. Di Martino et al. CLINICAL CANCER RESEARCH
- Silencing IDO in dendritic cells: A novel approach to enhance cancer immunotherapy in a murine breast cancer model
- (2012) Xiufen Zheng et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma
- (2012) Patrick A. Ott et al. INVESTIGATIONAL NEW DRUGS
- WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial
- (2012) Takashi Miyatake et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice
- (2012) Kathryn M. Kinross et al. JOURNAL OF CLINICAL INVESTIGATION
- Ovarian cancer progression is controlled by phenotypic changes in dendritic cells
- (2012) Uciane K. Scarlett et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer
- (2012) Lana E Kandalaft et al. Journal of Translational Medicine
- Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature
- (2012) Qiong-wen Zhang et al. PLoS One
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
- (2012) S. B. Willingham et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer
- (2012) Thomas Gardner et al. Human Vaccines & Immunotherapeutics
- Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer
- (2011) Samar Masoumi Moghaddam et al. CANCER AND METASTASIS REVIEWS
- A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
- (2011) Osama E. Rahma et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission
- (2011) Christina S. Chu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB)
- (2011) D.-G. Song et al. CANCER RESEARCH
- Tumor Suppressive MicroRNAs miR-34a/c Control Cancer Cell Expression of ULBP2, a Stress-Induced Ligand of the Natural Killer Cell Receptor NKG2D
- (2011) A. Heinemann et al. CANCER RESEARCH
- Skin delivery of short hairpin RNA of indoleamine 2,3 dioxygenase induces antitumor immunity against orthotopic and metastatic liver cancer
- (2011) Tzu-Ting Huang et al. CANCER SCIENCE
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use
- (2011) Zahra Hanaizi et al. EUROPEAN JOURNAL OF CANCER
- Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome
- (2011) Jia Huang et al. GENES CHROMOSOMES & CANCER
- Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study
- (2011) Kian Behbakht et al. GYNECOLOGIC ONCOLOGY
- Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer
- (2011) Ninke Leffers et al. INTERNATIONAL JOURNAL OF CANCER
- Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: A single-arm phase II study
- (2011) Renee Vermeij et al. INTERNATIONAL JOURNAL OF CANCER
- Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy
- (2011) DONGDONG WANG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Costimulation Through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-infiltrating Lymphocytes From Activation-induced Cell Death and Enhances Antitumor Effector Function
- (2011) Jessica Ann Hernandez-Chacon et al. JOURNAL OF IMMUNOTHERAPY
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- (2011) Omid Hamid et al. Journal of Translational Medicine
- CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
- (2011) Bin-Zhi Qian et al. NATURE
- Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
- (2011) Christian M. Metallo et al. NATURE
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD73: A Novel Target for Cancer Immunotherapy
- (2010) B. Zhang CANCER RESEARCH
- Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1
- (2010) M. J. Seltzer et al. CANCER RESEARCH
- ULBP2 and RAET1E NKG2D ligands are independent predictors of poor prognosis in ovarian cancer patients
- (2010) Roger W. McGilvray et al. INTERNATIONAL JOURNAL OF CANCER
- An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
- (2010) J. D. Mezrich et al. JOURNAL OF IMMUNOLOGY
- CTL Induction of Tumoricidal Nitric Oxide Production by Intratumoral Macrophages Is Critical for Tumor Elimination
- (2010) R. D. V. Miguel et al. JOURNAL OF IMMUNOLOGY
- The dynamic roles of TGF-β in cancer
- (2010) Erik Meulmeester et al. JOURNAL OF PATHOLOGY
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- (2010) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species
- (2010) S. Suzuki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function
- (2010) W. Hu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6
- (2009) S. Loges et al. BLOOD
- Arginase I–Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes
- (2009) Paulo C. Rodriguez et al. CANCER RESEARCH
- A Novel Cancer Therapy by Skin Delivery of Indoleamine 2,3-Dioxygenase siRNA
- (2009) M.-C. Yen et al. CLINICAL CANCER RESEARCH
- HIF-1: upstream and downstream of cancer metabolism
- (2009) Gregg L Semenza CURRENT OPINION IN GENETICS & DEVELOPMENT
- Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial
- (2009) Ninke Leffers et al. INTERNATIONAL JOURNAL OF CANCER
- Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis
- (2008) Kui Li et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Transcriptional control of mitochondrial biogenesis: the central role of PGC-1
- (2008) R. Ventura-Clapier et al. CARDIOVASCULAR RESEARCH
- Systematic Review and Meta-analysis of Ovarian Cancers: Estimation of Microsatellite-High Frequency and Characterization of Mismatch Repair Deficient Tumor Histology
- (2008) T. Pal et al. CLINICAL CANCER RESEARCH
- The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages
- (2008) Paola Allavena et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- In vitro metformin anti-neoplastic activity in epithelial ovarian cancer
- (2008) Walter H. Gotlieb et al. GYNECOLOGIC ONCOLOGY
- The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
- (2008) Heather R. Christofk et al. NATURE
- p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation
- (2008) Keiko Kawauchi et al. NATURE CELL BIOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started